Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell–Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome

Journal of the American College of Cardiology

Volumn 68, Issue 19, 2016, Pages 2086-2096

  Liang, Ping ^a,b,c   Sallam, Karim ^a   Wu, Haodi ^a   Li, Yingxin ^a   Itzhaki, Ilanit ^a   Garg, Priyanka ^a   Zhang, Ying ^a   Vermglinchan, Vittavat ^a   Lan, Feng ^a   Gu, Mingxia ^a   Gong, Tingyu ^a,b   Zhuge, Yan ^a   He, Chunjiang ^a   Ebert, Antje D ^a   Sanchez Freire, Veronica ^a   Churko, Jared ^a   Hu, Shijun ^a   Sharma, Arun ^a   Lam, Chi Keung ^a   Scheinman, Melvin M ^d   Bers, Donald M ^e   Wu, Joseph C ^a   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

action potential; arrhythmia; Ca2+ transient; gene expression; genome editing; SCN5A

Indexed keywords

CALCIUM ION; SODIUM CHANNEL NAV1.5; RNA; SCN5A PROTEIN, HUMAN;

ADULT; ARTICLE; BRUGADA SYNDROME; CARDIAC MUSCLE CELL; CASE REPORT; CELL DIFFERENTIATION; CELL POPULATION; CELL SPECIFICITY; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; EXPERIMENTAL STUDY; GENE EXPRESSION PROFILING; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN GENOME; HUMAN TISSUE; MALE; MIDDLE AGED; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SCN5A GENE; SENDAI VIRUS; SKIN FIBROBLAST; SODIUM CURRENT; ADOLESCENT; BIOSYNTHESIS; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HEART MUSCLE CONDUCTION SYSTEM; INDUCED PLURIPOTENT STEM CELL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PEDIGREE; POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADOLESCENT; ADULT; BRUGADA SYNDROME; CELL DIFFERENTIATION; ELECTROCARDIOGRAPHY; GENE EXPRESSION REGULATION; GENOTYPE; HEART CONDUCTION SYSTEM; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MIDDLE AGED; MYOCYTES, CARDIAC; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; PEDIGREE; PHENOTYPE; POLYMERASE CHAIN REACTION; RNA; YOUNG ADULT;

EID: 84994151982     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.07.779     Document Type: Article

References (42)

1. 1 Brugada, P., Brugada, J., Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 20 (1992), 1391–1396.
2. 2 Brugada, J., Brugada, R., Brugada, P., Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 108 (2003), 3092–3096.
3. 3 Antzelevitch, C., Brugada, P., Borggrefe, M., et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 111 (2005), 659–670.
4. 4 Veltmann, C., Schimpf, R., Echternach, C., et al. A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J 27 (2006), 2544–2552.
5. 5 Yan, G.X., Antzelevitch, C., Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100 (1999), 1660–1666.
6. 6 Meregalli, P.G., Wilde, A.A., Tan, H.L., Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more?. Cardiovasc Res 67 (2005), 367–378.
7. 7 Elizari, M.V., Levi, R., Acunzo, R.S., et al. Abnormal expression of cardiac neural crest cells in heart development: a different hypothesis for the etiopathogenesis of Brugada syndrome. Heart Rhythm 4 (2007), 359–365.
8. 8 Houser, S.R., Margulies, K.B., Murphy, A.M., et al. Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res 111 (2012), 131–150.
9. 9 Liang, P., Lan, F., Lee, A.S., et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127 (2013), 1677–1691.
10. 10 Moretti, A., Bellin, M., Welling, A., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363 (2010), 1397–1409.
11. 11 Matsa, E., Rajamohan, D., Dick, E., et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 32 (2011), 952–962.
12. 12 Wang, Y., Liang, P., Lan, F., et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J Am Coll Cardiol 64 (2014), 451–459.
13. 13 Itzhaki, I., Maizels, L., Huber, I., et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471 (2011), 225–229.
14. 14 Itzhaki, I., Maizels, L., Huber, I., et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J Am Coll Cardiol 60 (2012), 990–1000.
15. 15 Asimaki, A., Kapoor, S., Plovie, E., et al. Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. Sci Transl Med, 6, 2014, 240ra74.
16. 16 Kim, C., Wong, J., Wen, J., et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 494 (2013), 105–110.
17. 17 Wang, G., McCain, M.L., Yang, L., et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med 20 (2014), 616–623.
18. 18 Yazawa, M., Hsueh, B., Jia, X., et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471 (2011), 230–234.
19. 19 Carvajal-Vergara, X., Sevilla, A., D'Souza, S.L., et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465 (2010), 808–812.
20. 20 Sun, N., Yazawa, M., Liu, J., et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med, 4, 2012, 130ra47.
21. 21 Karakikes, I., Stillitano, F., Nonnenmacher, M., et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun, 6, 2015, 6955.
22. 22 Wu, H., Lee, J., Vincent, L.G., et al. Epigenetic regulation of phosphodiesterases 2A and 3A underlies compromised beta-adrenergic signaling in an iPSC model of dilated cardiomyopathy. Cell Stem Cell 17 (2015), 89–100.
23. 23 Hinson, J.T., Chopra, A., Nafissi, N., et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science 349 (2015), 982–986.
24. 24 Lan, F., Lee, A.S., Liang, P., et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12 (2013), 101–113.
25. 25 Ebert, A.D., Kodo, K., Liang, P., et al. Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system. Sci Transl Med, 6, 2014, 255ra130.
26. 26 Burridge, P.W., Li, Y.F., Matsa, E., et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med 22 (2016), 547–556.
27. 27 Matsa, E., Burridge, P.W., Yu, K.H., et al. Transcriptome profiling of patient-specific human iPSC-cardiomyocytes predicts individual drug safety and efficacy responses n vitro. Cell Stem Cell 19 (2016), 311–312.
28. 28 Lian, X., Hsiao, C., Wilson, G., et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 109 (2012), E1848–E1857.
29. 29 Calloe, K., Refaat, M.M., Grubb, S., et al. Characterization and mechanisms of action of novel NaV1.5 channel mutations associated with Brugada syndrome. Circ Arrhythm Electrophysiol 6 (2013), 177–184.
30. 30 Glatter, K.A., Wang, Q., Keating, M., et al. Effectiveness of sotalol treatment in symptomatic Brugada syndrome. Am J Cardiol 93 (2004), 1320–1322.
31. 31 Gaborit, N., Wichter, T., Varro, A., et al. Transcriptional profiling of ion channel genes in Brugada syndrome and other right ventricular arrhythmogenic diseases. Eur Heart J 30 (2009), 487–496.
32. 32 Sallam, K., Li, Y., Sager, P.T., et al. Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ Res 116 (2015), 1989–2004.
33. 33 Chen, Q., Kirsch, G.E., Zhang, D., et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392 (1998), 293–296.
34. 34 Shin, D.J., Kim, E., Park, S.B., et al. A novel mutation in the SCN5A gene is associated with Brugada syndrome. Life Sci 80 (2007), 716–724.
35. 35 Chiang, K.C., Lai, L.P., Shieh, R.C., Characterization of a novel Nav1.5 channel mutation, A551T, associated with Brugada syndrome. J Biomed Sci, 16, 2009, 76.
36. 36 Davis, R.P., Casini, S., van den Berg, C.W., et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 125 (2012), 3079–3091.
37. 37 Cerrone, M., Lin, X., Zhang, M., et al. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. Circulation 129 (2014), 1092–1103.
38. 38 Baroudi, G., Pouliot, V., Denjoy, I., et al. Novel mechanism for Brugada syndrome: defective surface localization of an SCN5A mutant (R1432G). Circ Res 88 (2001), E78–E83.
39. 39 Roden, D.M., Repolarization reserve: a moving target. Circulation 118 (2008), 981–982.
40. 40 Martin, C.A., Siedlecka, U., Kemmerich, K., et al. Reduced Na(+) and higher K(+) channel expression and function contribute to right ventricular origin of arrhythmias in Scn5a+/- mice. Open Biol, 2, 2012, 120072.
41. 41 Boukens, B.J., Sylva, M., de Gier-de Vries, C., et al. Reduced sodium channel function unmasks residual embryonic slow conduction in the adult right ventricular outflow tract. Circ Res 113 (2013), 137–141.
42. 42 Sayed, N., Liu, C., Wu, J.C., Translation of human-induced pluripotent stem cells: from clinical trial in a dish to precision medicine. J Am Coll Cardiol 67 (2016), 2161–2176.